Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?
Authors
Keywords
Lymphoma, CLL, CD20, Monoclonal antibodies, Rituximab, Immunotherapy, Biosimilar
Journal
Current Oncology Reports
Volume 20, Issue 12, Pages -
Publisher
Springer Nature
Online
2018-11-27
DOI
10.1007/s11912-018-0748-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A tale of two antibodies: obinutuzumab versus rituximab
- (2018) Ciara L. Freeman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Progress in Advanced-Stage Follicular Lymphoma
- (2018) Jonathan W. Friedberg JOURNAL OF CLINICAL ONCOLOGY
- Deleting Malignant B Cells With Second-Generation Anti-CD20 Antibodies
- (2018) Josh Sopp et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety
- (2018) Wolfgang Hiddemann et al. JOURNAL OF CLINICAL ONCOLOGY
- Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
- (2018) Timothy M. Pierpont et al. Frontiers in Oncology
- Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial
- (2018) Paula Cramer et al. LANCET ONCOLOGY
- Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study
- (2017) Pieternella Lugtenburg et al. HAEMATOLOGICA
- LONG-TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW-UP
- (2017) M. Montillo et al. HEMATOLOGICAL ONCOLOGY
- Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis
- (2017) Yougen Wu et al. Hematology
- Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study
- (2017) Gustaaf W. van Imhoff et al. JOURNAL OF CLINICAL ONCOLOGY
- The high price of anticancer drugs: origins, implications, barriers, solutions
- (2017) Vinay Prasad et al. Nature Reviews Clinical Oncology
- Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
- (2017) Robert Marcus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study
- (2017) Pieternella Lugtenburg et al. HAEMATOLOGICA
- Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
- (2017) Michael J. E. Marshall et al. Frontiers in Immunology
- Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
- (2017) Andrew Davies et al. Lancet Haematology
- Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study
- (2017) Wojciech Jurczak et al. Lancet Haematology
- Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma
- (2016) Vikram Gota et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial
- (2016) Sarit Assouline et al. Lancet Haematology
- Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries
- (2016) Erwin De Cock et al. PLoS One
- Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia
- (2015) Sarit Assouline et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Biosimilar monoclonal antibodies in lymphoma: a critical appraisal
- (2015) Catherine Rioufol et al. Expert Review of Anticancer Therapy
- Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma
- (2015) G. Cartron et al. HAEMATOLOGICA
- Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
- (2015) Laurie H. Sehn et al. JOURNAL OF CLINICAL ONCOLOGY
- Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
- (2015) Carla Casulo et al. JOURNAL OF CLINICAL ONCOLOGY
- FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin
- (2015) Michal Pyzik et al. JOURNAL OF IMMUNOLOGY
- Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
- (2015) Peter Hillmen et al. LANCET
- Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study
- (2015) Marinus H J van Oers et al. LANCET ONCOLOGY
- Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma
- (2015) G. Cartron et al. HAEMATOLOGICA
- Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro
- (2015) Jennifer D. Könitzer et al. PLoS One
- Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma
- (2014) Shaker Dakhil et al. LEUKEMIA & LYMPHOMA
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Postulated Mechanisms of Resistance of B-Cell Non-Hodgkin Lymphoma to Rituximab Treatment Regimens: Strategies to Overcome Resistance
- (2014) Benjamin Bonavida SEMINARS IN ONCOLOGY
- Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom
- (2014) Simon Rule et al. JOURNAL OF MEDICAL ECONOMICS
- Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab
- (2013) J. Golay et al. BLOOD
- Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
- (2013) O Shpilberg et al. BRITISH JOURNAL OF CANCER
- Rituximab biosimilars
- (2013) Edward M Vital et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study
- (2013) Gilles A. Salles et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties
- (2013) S. Rafiq et al. JOURNAL OF IMMUNOLOGY
- Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
- (2013) S. Herter et al. MOLECULAR CANCER THERAPEUTICS
- Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway
- (2012) J. Honeychurch et al. BLOOD
- Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
- (2012) G. Salles et al. BLOOD
- A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies
- (2012) L. H. Sehn et al. BLOOD
- Rituximab resistance
- (2011) Andrew R. Rezvani et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
- (2011) W. Alduaij et al. BLOOD
- Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
- (2011) G. Niederfellner et al. BLOOD
- Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab
- (2011) L. Bologna et al. JOURNAL OF IMMUNOLOGY
- Acceptable changes in quality attributes of glycosylated biopharmaceuticals
- (2011) Martin Schiestl et al. NATURE BIOTECHNOLOGY
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies
- (2010) M Le Garff-Tavernier et al. LEUKEMIA
- Ofatumumab
- (2010) Michael J. Keating et al. NATURE REVIEWS DRUG DISCOVERY
- The Average Body Surface Area of Adult Cancer Patients in the UK: A Multicentre Retrospective Study
- (2010) Joseph J. Sacco et al. PLoS One
- CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies
- (2010) Stephen A. Beers et al. SEMINARS IN HEMATOLOGY
- Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16
- (2008) Christophe de Romeuf et al. BRITISH JOURNAL OF HAEMATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now